The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Central Nervous System Therapeutics Market’s Market Value Anticipated To Evolve From 2026 To 2030?
The central nervous system therapeutics market has experienced significant expansion in recent years. It is anticipated to increase from $134.99 billion in 2025 to $147.29 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.1%. Historically, this market’s development has been propelled by factors such as the rising prevalence of depression and epilepsy, an expanding aging population, restricted treatment options for degenerative disorders, an increase in hospitalization rates for CNS conditions, and the growth of hospital and clinic infrastructure.
The market for central nervous system therapeutics is projected to experience robust expansion over the coming years. It is anticipated to reach $206.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. This anticipated growth during the forecast period is attributable to several factors, including the creation of new neuroprotective agents, an increase in biologics and gene-based therapies, greater investment in neuroscience research, the growing acceptance of personalized medicine, and wider availability of CNS treatments in developing markets. Key trends expected during the forecast period involve the increasing occurrence of neurological and mental health conditions, the expanding use of combination therapies for CNS diseases, a heightened emphasis on managing diseases over the long term and controlling symptoms, the growth of homecare-based CNS treatment options, and enhanced drug formulations that improve blood-brain barrier penetration.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp
Which Major Factors Are Contributing To The Development Of The Central Nervous System Therapeutics Market?
The growing incidence of mental health disorders is projected to propel the expansion of the central nervous system therapeutics market. Mental health disorders refer to a broad spectrum of conditions affecting an individual’s thinking, feeling, behavior, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The increasing prevalence of these disorders is attributed to greater exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to issues like anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics are instrumental in treating mental health disorders by targeting the specific brain chemicals and neural pathways involved in mood, behavior, and cognition. For instance, a report from Bristol City Council in December 2025 highlighted that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, marking a 6.0% rise from 2021-22. Therefore, the increasing prevalence of mental health disorders is driving the growth of the central nervous system therapeutics market.
How Is The Central Nervous System Therapeutics Market Examined Through Segment Analysis?
The central nervous system therapeutics market covered in this report is segmented –
1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes
2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
4) By Application: Hospital, Clinic, Homecare, Other Applications
Subsegments:
1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics
2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents
3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids
4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives
5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief
6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents
Which Trends Are Expected To Shape The Central Nervous System Therapeutics Market?
Leading companies in the central nervous system therapeutics market are concentrating on developing innovative solutions, such as capsid engineering, to improve targeted gene delivery, therapeutic efficacy, and blood-brain barrier penetration for more effective treatment of neurological disorders. Capsid engineering involves the modification and optimization of the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), utilized in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a biotechnology company based in France, launched coAAV CSF 01, a novel adeno associated virus (AAV) for central nervous system (CNS) delivery, leveraging their proprietary ALIGATER platform. This new vector demonstrated significantly enhanced transduction efficiency and safety when compared to AAV9. When delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, equivalent expression levels to AAV9 were attained at just one-fifth of the dose, highlighting its superior potency. Additionally, the vector showed substantially reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These results underscore the vector’s potential to enhance CNS gene therapy outcomes with improved precision and lower systemic risk.
Who Are The Major Companies Operating In The Central Nervous System Therapeutics Market?
Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.
Access The Complete Central Nervous System Therapeutics Market Report:
Which Region Is The Primary Market For The Central Nervous System Therapeutics Market?
North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Central Nervous System Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp
Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2026, By The Business Research Company
Insurance Business Process Outsourcing Market Report 2026
Outsourced Customer Care Services Market Report 2026
Outsourced Software Testing Services Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model